Executive Summary
This single-day snapshot reveals $2.9B in significant federal contract modifications, dominated by IT services ($1.6B+ across top awards) signaling sustained government demand amid fiscal 2026 planning. Leidos captures 38% of value with two mega-awards ($1.13B total), bolstering defense/IT peers like General Dynamics and Oracle, while DHS/VA healthcare and security contracts provide multi-year revenue backstops through 2033.
Investors should prioritize unexercised options ($1.5B+ potential) and extensions for upside, tempered by firm-fixed-price execution risks.
Materiality, sentiment, and priority are scored by Gunpowder’s analysis pipeline. How we score filings →
Tracking the trend? Catch up on the prior Significant Contract Modifications ($10M+) digest from March 18, 2026.
Investment Signals (4)
- Leidos IT dominance with $1.13B awards (HIGH)▲
Leidos secures SSA ($1.06B) and DHS ($67M) contracts for IT management and equipment maintenance, with $906M outlayed and $425M options ceiling, affirming steady civilian/defense revenue.
- IT services surge across agencies (HIGH)▲
Nine IT-focused awards total $1.6B (55% of stream), including Oracle VA EHRM ($176M, $784M ceiling), Salient HUD ($95M, $245M ceiling), and Deloitte VA cyber ($67M, $185M ceiling), with rapid outlays signaling execution momentum.
- DHS/CBP security tech commitments (HIGH)▲
Four DHS awards ($407M total) to Rapiscan ($186M portals), Smiths Detection ($77M rail systems), Steampunk ($75M HR IT), and Leidos ($67M maintenance) extend to 2031+, with $215M outlayed.
- VA medical supplies locked for 2026 (MEDIUM)▲
Medline secures $138M in back-to-back one-month prime vendor orders for Jan/Feb 2026, signaling predictable wholesaling revenue amid VA procurement stability.
Risk Flags (3)
- Execution [HIGH RISK]▼
Firm fixed price prevalent in 13/18 contracts ($2.3B value) exposes winners to cost overruns without reimbursement, especially over long periods to 2033.
- Market [MEDIUM RISK]▼
Unexercised options total $1.5B+ across awards; non-exercise could cap revenue at current obligations.
- Competitive [MEDIUM RISK]▼
Heavy subawards (e.g., $145M Leidos SSA, $31M Gen Dynamics IT) indicate 20-45% pass-through, potentially eroding prime margins.
Opportunities (3)
- ◆
$1.5B+ in unexercised options (e.g., Oracle $608M, Leidos DHS $183M, Salient $151M) offer scalable revenue if exercised.
- ◆
Extensions to 2029-2033 in 8 contracts (e.g., Rapiscan, Life Science Logistics) amid multi-year IT/security needs could add $500M+ duration.
- ◆
Repeat wins like Leidos (SSA/DHS), Medline (VA months), Gen Dynamics position for follow-ons in IT/health.
Sector Themes (3)
- ◆
IT/telecom awards comprise 55% ($1.6B) across SSA, VA, HUD, DHS, with non-competitive and competed wins signaling entrenched vendor relationships.
- ◆
20% of value ($580M) in detection/maintenance contracts to 2031+, reflecting sustained enforcement priorities.
- ◆
HHS/VA awards ($800M+) in insurance, labs, warehousing, supplies lock revenue through 2029.
Watch List (4)
- 👁
{"entity"=>"Leidos Holdings", "reason"=>"38% stream capture with $425M options upside across SSA/DHS", "trigger"=>"Q1 2026 option exercises or outlay acceleration >$100M"}
- 👁
{"entity"=>"Medline Industries", "reason"=>"$138M VA 2026 lock-in signals monthly prime vendor cadence", "trigger"=>"Additional 2026 monthly awards >$60M"}
- 👁
{"entity"=>"Oracle (Health Gov Services)", "reason"=>"$608M VA EHRM options in non-competed health IT", "trigger"=>"Funding outlays commencing post-$0 current"}
- 👁
{"entity"=>"DHS/CBP contractors (Rapiscan, Smiths, Steampunk)", "reason"=>"$407M cluster to 2031+ amid border priorities", "trigger"=>"Extension notices or new task orders"}
Get daily alerts with 4 investment signals, 3 risk alerts, 3 opportunities and full AI analysis of all 18 filings
$30/mo after a 14-day free trial — no credit card required. See pricing or explore intelligence streams.
More from: Significant Contract Modifications ($10M+)
🇺🇸 More from United States
View all →May 27, 2026
US Pre-Market SEC Filings Roundup — May 27, 2026
US Pre-Market SEC Filings Roundup
May 27, 2026
S&P 500 Technology Sector SEC Filings — May 27, 2026
S&P 500 Technology Sector SEC Filings
May 27, 2026
Orphan Drug Approvals — May 27, 2026
Orphan Drug Approvals
May 27, 2026
Big Pharma Approvals — May 27, 2026
Big Pharma Approvals